The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

Haematologica. 2017 Nov;102(11):e447-e451. doi: 10.3324/haematol.2017.168930. Epub 2017 Aug 24.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrylamides / pharmacology*
  • Agammaglobulinaemia Tyrosine Kinase
  • Antineoplastic Agents / pharmacology*
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Enzyme Activation / drug effects
  • Humans
  • Lenalidomide
  • Lymphoma, Mantle-Cell / drug therapy
  • Lymphoma, Mantle-Cell / genetics*
  • Lymphoma, Mantle-Cell / metabolism*
  • Mutation*
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / genetics*
  • Protein Kinase Inhibitors / pharmacology
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / pharmacology*
  • Thalidomide / analogs & derivatives*
  • Thalidomide / pharmacology

Substances

  • Acrylamides
  • Antineoplastic Agents
  • NF-kappa B
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thalidomide
  • spebrutinib
  • Protein-Tyrosine Kinases
  • Agammaglobulinaemia Tyrosine Kinase
  • Lenalidomide